|
Feb 18
|
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Jan 23
|
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
|
|
Jan 16
|
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS
|
|
Jan 16
|
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
|
|
Jan 15
|
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
|
|
Jan 7
|
InflaRx Announces Participation in January Events in San Francisco
|